Effects of synthetic monocyte chemotactic protein-1 fragment 65–76 on neointima formation after carotid artery balloon injury in rats

  • N. B. Kukhtina
  • P. P. Bashtrykov
  • Zh. D. Bespalova
  • M. V. Sidorova
  • T. I. Aref’eva
  • V. O. Sokolov
  • T. L. Krasnikova
Article
First Online:
Received:

The effects of the synthetic monocyte chemotactic protein-1 (MCP-1) peptide fragment 65–76 (peptide X) on the development of neointima after balloon injury to the carotid artery were studied. The agent was given i.m. at a dose of 33 µg/kg once daily for 28 days after balloon injury. Animals given peptide showed significant suppression of neointima growth 4 and 7 days after lesioning, as indicated by morphometric analysis of sections of lesioned arteries. On days 14 and 28, there were no significant differences in neointima formation in rats given and not given peptide. Peptide administration was not accompanied by any changes in C-reactive peptide concentrations, leukocyte counts, or the population composition of peripheral blood lymphocytes. Use of synthetic peptide X as an inhibitor of leukocyte migration during angioplasty may, along with traditional treatments, decrease the risk of restenosis.

Key Words

MCP-1 peptide X neointima carotid artery balloon injury in rats 
This is a preview of subscription content, log in to check access.

References

  1. 1.
    O. P. Il'inskaya, E. Yu. Kudryashova, Yu. G. Antropova, N. I. Kalinina, M. A. Solomatina, A. Bobik, and É. M. Tararak, “The origin of neointimal cells formed in rat carotid artery after balloon angioplasty,” Tsitologiya, 7, 678–689 (2003).Google Scholar
  2. 2.
    T. L. Krasnikova, T. I. Aref'eva, and N. B. Kukhtina, “Chemokines, chemokine receptors, and atherogenesis,” Usp. Sovrem. Biol., 123, No. 35, 505–513 (2003).Google Scholar
  3. 3.
    T. L. Krasnikova, T. I. Aref'eva, M. G. Melekhov, N. B. Kukhtina, M. V. Sidorova, A. S. Molokoedov, B. N. Bushuev, Zh. D. Bespalova, and E. I. Chazov, “A peptide with the sequence of residues 66–77 of monocyte chemotactic factor (MCP-1) which inhibits inflammation in experimental animals,” Dokl. Akad. Nauk., 404, 402–405 (2005).Google Scholar
  4. 4.
    N. B. Kukhtina, T. I. Aref'eva, A. M. Aref'eva, R. S. Akchurin, and T. L. Krasnikova, “Chemokine and cytokine expression in atherosclerotic plaques and the arterial intima in patients with ischemic heart disease,” Ter. Arkhiv. (2008) (in press).Google Scholar
  5. 5.
    M. V. Sidorova, A. S. Molokoedov A. A. Az'myko, T. I. Aref'eva, M. G. Melekhov, N. B. Kukhtina, T. L. Krasnikova, Zh. D. Bespalova, and V. N. Bushuev, “A peptide fragment (66–77) of monocyte chemotactic protein 1 and its retro-enantio analog inhibit cell migration in vivo and in vitro,” Bioorgan. Khim., 32, No. 2, 161–168 (2006).Google Scholar
  6. 6.
    E. I. Chazov, T. L. Krasnikova, Zh. D. Bespalova, N. B. Kukhtina, M. G. Melekhov, T. I. Aref'eva, M. V. Sidorova, A. S. Molokoedov, T. E. Gvozdik, B. M. Mart'yanov, V. V. Pozdeev, V. B. Sergienko, and T. L. Bushueva, “Inhibition of monocyte and granulocyte migration in vivo by peptide sequence (65–76) of monocyte chemotactic protein-1 (MCP-1),” Dokl. Ros. Akad. Nauk., 411, No. 2, 270–272 (2006).Google Scholar
  7. 7.
    P. Aukrust, T. Ueland, F. Muller, A. K. Andreassen, I. Nordoy H. Aas, J. Kjekshus, S. Simonsen, S. S. Froland, and L. Gullestad, “Elevated circulating levels of C-C chemokines in patients with congestive heart failure,” Circulation, 97, No. 12, 1136–1143 (1998).PubMedGoogle Scholar
  8. 8.
    L. Boring, J. Gosling, M. Cleary, and I. F. Charo, “Decreased lesion formation in CCR2-/-mice reveals a role for chemokines in the initiation of atherosclerosis,” Nature, 394, No. 6696, 894–897 (1998).PubMedCrossRefGoogle Scholar
  9. 9.
    Q. Capers et al., “Monocyte chemoattractant protein-1 expression in aortic tissues of hypertensive rats,” Hypertension, 30, No. 6, 1397–1402 (1997).PubMedGoogle Scholar
  10. 10.
    M. W. Carr, S. J. Roth, E. Luther, S. S. Rose, and T. A. Springer, “Monocyte chemoattractant protein 1 acts as a T-lymphocyte chemoattractant,” Proc. Natl. Acad. Sci. USA, 91, No. 9, 3652–2656 (1994).PubMedCrossRefGoogle Scholar
  11. 11.
    P. Conti, X. Pang, W. Boucher, R. Letourneau, M. Reale, R. C. Barbacane, J. Thibault, and T. C. Theoharides, “Monocyte chemotactic protein-1 is a proinflammatory chemokine in rat skin injection sites and chemoattracts basophilic granular cells,” Int. Immunol., 9, No. 10, 1563–1570 (1997).PubMedCrossRefGoogle Scholar
  12. 12.
    Y. Furukawa, A. Matsumori, M. Ohashi, T. Shioi, K. Ono, A. Harada, K. Matsushima, and S. Sasayama, “Anti-monocyte chemoattractant protein-1/monocyte chemotactic and activating factor antibody inhibits neointimal hyperplasia in injured rat carotid arteries,” Circ. Res., 84, No. 3, 306–314 (1999).PubMedGoogle Scholar
  13. 13.
    S. D. Gertz, L. W. Gimple, M. Ragosta, W. C. Roberts, H. L. Harber, W. R. Powers, L. S. Perez, and I. J. Sarembock, “Response of femoral arteries of cholesterol-fed rabbits to balloon angioplasty with or without laser: emphasis on the distribution of foam cells,” Exptl. Mol. Pathol., 59, No. 3, 225–243 (1993).CrossRefGoogle Scholar
  14. 14.
    L. Gu, Y. Okada, S. K. Clinton, C. Gerard, G. K. Sukhova, P. Libby, and B. J. Rollins, “Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice, ” Mol. Cell, 2, No. 2, 275–281 (1998).PubMedCrossRefGoogle Scholar
  15. 15.
    L. Gu, S. C. Tseng, and B. J. Rollins, “Monocyte chemoattractant protein-1,” Chem. Immunol., 72, 7–29 (1999).PubMedCrossRefGoogle Scholar
  16. 16.
    Y. Kitta, J. E. Obata, H. Takano, T. Nakamura, Y. Kodama, D. Fujioka, Y. Saito, K. I. Kawabata, A. Mende, T. Kobayashi, and K. Kugiyama, “Echolucent carotid plaques predict in-stent restenosis after bare metal stenting in native coronary arteries,” Atherosclerosis (2007) (in press).Google Scholar
  17. 17.
    A. Lafont, L. A. Guzman, P. L. Whitlow, M. Goormastic, J. F. Cornhill, and G. M. Chisholm, “Restenosis after experimental angioplasty. Intimal, medial, and adventitial changes associated with constrictive remodeling,” Circ. Res., 76, No. 6, 996–1002 (1995).PubMedGoogle Scholar
  18. 18.
    P. Libby, “Inducible gene expression in vascular wall cells and lesional leukocytes,” J. Vasc. Surg., 15, No. 5, 916–917 (1992).PubMedGoogle Scholar
  19. 19.
    P. Libby, “Current concepts of the pathogenesis of the acute coronary syndromes,” Circulation, 104, No. 3, 365–372 (2001).PubMedGoogle Scholar
  20. 20.
    A. Lovqvist, H. Emanuelsson, J. Nilsson, H. Lundqvist, and J. Carlsson, “Pathophysiological mechanisms for restenosis following coronary angioplasty: possible preventive alternatives,” J. Intern. Med., 233, No. 3, 215–226 (1993).PubMedCrossRefGoogle Scholar
  21. 21.
    D. H. McDermott, Q. Yang, S. Kathiresan, L. A. Cupples, J. M. Massaro, J. F. Keaney, Jr., M. G. Larson, R. S. Vasan, J. N. Hirschhorn, C. J. O'Donnell, C. J. Murphy, and E. J. Benjamin, “CCL2 polymorphisms are associated with serum monocyte chemoattractant protein-1 levels and myocardial infarction in the Framingham Heart Study,” Circulation, 112, No. 8, 1113–1120 (2005).PubMedCrossRefGoogle Scholar
  22. 22.
    R. H. Mahta, R. Zahn, M. Hochadel, T. Ischinger, J. Jung, K. E. Hauptmann, B. Mark, U. Zeymer, A. Schramm, and J. Senges, “Comparison of inhospital outcomes of patients with versus without previous carotid endarterectomy undergoing carotid stenting (from the German ALKK CAS Registry),” Amer. J. Cardiol., 99, No. 9, 1288–1293 (2007).CrossRefGoogle Scholar
  23. 23.
    N. Mukaida, A. Jarada, and K. Matsushima, “Interleukin-8 (IL-8) and monocyte chemotactic and activating factor (MCAF/MCP-1), chemokines essentially involved in inflammatory and immune reactions,” Cytokine Growth Factor Rev., 9, No. 1, 9–23 (1998).PubMedCrossRefGoogle Scholar
  24. 24.
    J. Reckless and D. J. Grainger, “Identification of oligopeptide sequences which inhibit migration induced by a wide range of chemokines,” Biochem. J., 340, No. 3, 803–811 (1999).PubMedCrossRefGoogle Scholar
  25. 25.
    R. A. Robinson, T. Yoshimura, E. J. Leonard, S. Tanaka, P. R. Griffin, J. Shabanowitz, D. F. Hunt, and E. Appella, “Complete amino acid sequence of a human monocyte chemoattractant, a putative mediator of cellular immune reactions,” Proc. Natl. Acad. Sci. USA, 86, No. 6, 1850–1854 (1989).PubMedCrossRefGoogle Scholar
  26. 26.
    B. J. Rollins, P. Stier, T. Ernst, and G. G. Wong, “The human homolog of the JE gene encodes a monocyte secretory protein,” Mol. Cell Biol., 9, No. 11, 4687–4695 (1989).PubMedGoogle Scholar
  27. 27.
    B. J. Rollins, T. Yoshimura, E. J. Leonard, and J. S. Prober, “Cytokine-activated human endothelial cells synthesize and secrete a monocyte chemoattractant, MCP-1/JE,” Amer. J. Pathol., 136, No. 6, 1229–1233 (1990).Google Scholar
  28. 28.
    R. Ross, “Atherosclerosis is an inflammatory disease,” Amer. Heart J., 138, No. 5, part 2, S419–S420 (1999).PubMedCrossRefGoogle Scholar
  29. 29.
    P. W. Serruys, D. P. Foley, and P. J. de Feyter, “Restenosis after coronary angioplasty: a proposal of new comparative approaches based on quantitative angiography,” Brit. Heart J., 68, No. 4, 417–424 (1992).PubMedCrossRefGoogle Scholar
  30. 30.
    T. Shioi, A. Matsumori, Y. Kihara, M. Inoko, K. Ono, Y. Iwanaga, T. Yamada, A. Iwasaka, K. Matsushima, and S. Sasayama, “Increased expression of interleukin-1 beta and monocyte chemotactic and activating factor/monocyte chemoattractant protein-1 in the hypertrophied and failing heart with pressure overload,” Circ. Res., 81, No. 5, 664–671 (1997).PubMedGoogle Scholar
  31. 31.
    M. B. Taubman, B. J. Rollins, M. Poon, J. Marumur, R. S. Green, B. C. Berk, and B. Nadal-Ginard, “JE mRNA accumulates rapidly in aortic injury and in platelet-derived growth factor-stimulated vascular smooth muscle cells,” Circ. Res., 70, No. 2, 314–325 (1992).PubMedGoogle Scholar
  32. 32.
    A. J. Valente, D. T. Graves, C. E. Vialle-Valentin, R. Delgado, and C. J. Schwartz, “Purification of a monocyte chemotactic factor secreted by nonhuman primate vascular cells in culture,” Biochemistry, 27, No. 11, 4162–4168 (1988).PubMedCrossRefGoogle Scholar
  33. 33.
    S. Yla-Herttuala, B. A. Lipton, M. E. Rosenfeld, T. Sarkioja, T. Yoshimura, E. J. Leonard, J. L. Witztum, and D. Steinberg, “Expression of monocyte chemoattractant protein 1 in macrophagerich areas of human and rabbit atherosclerotic lesions,” Proc. Natl. Acad. Sci. USA, 88, No. 12, 5252–5256 (1991).PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, Inc. 2009

Authors and Affiliations

  • N. B. Kukhtina
    • 1
  • P. P. Bashtrykov
    • 1
  • Zh. D. Bespalova
    • 1
  • M. V. Sidorova
    • 1
  • T. I. Aref’eva
    • 1
  • V. O. Sokolov
    • 1
  • T. L. Krasnikova
    • 1
  1. 1.Federal State Cardiological Scientific-Industrial Complex RosmedtekhnologiiMoscowRussia

Personalised recommendations